ARMP logo

Armata Pharmaceuticals, Inc. Stock Price

NYSEAM:ARMP Community·US$114.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ARMP Share Price Performance

US$3.17
0.81 (34.32%)
US$3.17
0.81 (34.32%)
Price US$3.17

ARMP Community Narratives

There are no narratives available yet.

Recent ARMP News & Updates

Armata Pharmaceuticals, Inc. Key Details

US$6.9m

Revenue

US$34.5m

Cost of Revenue

-US$27.7m

Gross Profit

-US$2.0m

Other Expenses

-US$25.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.71
Gross Margin
-402.88%
Net Profit Margin
-374.30%
Debt/Equity Ratio
-161.6%

Armata Pharmaceuticals, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Low risk with weak fundamentals.

3 Risks
0 Rewards

About ARMP

Founded
n/a
Employees
60
CEO
Deborah Birx
WebsiteView website
www.armatapharma.com

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›